Approval of new antidepressant likely to reopen debate on attack method

Cymbalta, a new antidepressant drug expected to get FDA approval this summer, addresses the ailment by attacking two of the brain's chemicals, including norepinephrine, believed by some scientists to be linked to depression. The launch of Eli Lilly's new drug is likely to ignite new debate over whether drugs that seek to attack two chemicals at once are better than those that concentrate on a single source of depression, such as Lilly's own Prozac, a selective serotonin reuptake inhibitor.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC